보고서 요약(국문)

개요
전 세계 이소시트레이트 탈수소효소 억제제 시장은 2022년 XX억 달러에 달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률로 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
이소시트레이트 탈수소효소 억제제는 IDH 효소의 활성을 변화시켜 α-케토글루타르산을 D-2-하이드록시글루타르산으로 환원시킵니다. 이소시트레이트 탈수소효소 1(IDH1) 억제제는 다양한 유형의 암 치료에 사용되는 약물입니다. IDH1은 이소시트레이트 탈수소효소라는 효소를 생성하는 유전자입니다.
이 억제제는 변이된 IDH 효소를 표적으로 삼아 비정상적인 활성을 억제하고 암세포 증식을 저해합니다. 치료 목표는 종양학에서 표적 접근법을 통해 암세포의 분화 및 세포사멸을 유도하는 것입니다.

시장 동향
급성 골수성 백혈병의 유병률 증가
급성 골수성 백혈병의 유병률 증가는 시장 성장의 중요한 동인으로 작용합니다. 급성 골수성 백혈병은 골수 세포가 정상적인 백혈구, 적혈구 및 혈소판 생성을 방해하면서 빠르게 진행됩니다.
예를 들어, 미국 임상 종양학회(ASCO)에 따르면 급성 골수성 백혈병은 모든 성인 백혈병 사례의 31%를 차지합니다. 2023년 미국에서는 이 질병으로 인해 약 11,310명이 사망한 것으로 추산됩니다.
또한, 인도 의학 연구 위원회(ICMR)에 따르면 연간 발생률은 10만 명당 2~3명입니다. 발생률은 연령이 증가함에 따라 높아지며, 30세 미만에서는 10만 명당 1명 미만이고 75세 이상에서는 10만 명당 17명입니다.

또한, 이소시트레이트 탈수소효소 억제제에 대한 임상 시험 증가 및 신약 승인과 같은 주요 성장 동력이 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.
이소시트레이트 탈수소효소 억제제 관련 부작용
IDH 억제제의 부작용은 시장 성장을 저해할 수 있습니다. 이소시트레이트 탈수소효소 억제제의 일반적인 부작용으로는 피로, 헤모글로빈 수치 감소, 백혈구 수 감소, 콜레스테롤 증가, 메스꺼움 및 전해질 감소 등이 있습니다.
세분화 분석
전 세계 이소시트레이트 탈수소효소 억제제 시장은 유형, 적용 분야, 투여 경로 및 지역별로 세분화됩니다.
IDH1 억제제 부문은 시장 점유율의 약 41.9%를 차지했습니다.
IDH1 억제제 부문은 임상 시험 건수 증가로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. IDH1 억제제에 대한 임상 시험은 총 33건이 진행되었습니다.

예를 들어, clinicaltrial.gov에 따르면, 2021년 3월 1일 M.D. 앤더슨 암센터는 경구용 데시타빈/세다주리딘과 베네토클락스를 표적 변이 IDH1 억제제인 이보시데닙과 병용하는 임상시험을 시작했습니다. 현재 2상 임상시험이 진행 중이며, 예상 완료일은 2024년 11월입니다.
또한, 2023년 1월 4일 프랑스 골수이형성증 연구회(Groupe Francophone des Myelodysplasies)는 IDH1 변이 골수이형성증 환자를 대상으로 IDH1 억제제의 2상 다기관 임상시험을 시작했습니다. 예상 완료일은 2023년 4월입니다. 따라서 위와 같은 요인들로 인해 해당 부문이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.

지리적 분석
북미는 전 세계 이소시트레이트 탈수소효소 억제제 시장에서 상당한 점유율을 차지할 것으로 예상됩니다.
전 세계 이소시트레이트 탈수소효소 억제제 시장은 북미, 유럽, 아시아 태평양, 남미, 중동 및 아프리카로 구분됩니다.
북미는 담관암 발병률 증가, 신약 승인, 의료비 지출 증가 등의 요인으로 인해 상당한 시장 점유율을 유지해 왔으며, 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.
예를 들어, 2022년 12월 미국 식품의약국(FDA)은 IDH1 변이가 있는 재발성 또는 불응성 급성 골수성 백혈병 성인 환자를 위한 레즐리디아(올루타시데닙) 캡슐을 승인했습니다.
또한, 미국에서는 매년 약 8,000명이 담관암 진단을 받고 있으며, 담관암 환자의 최대 20%가 IDH1 변이를 가지고 있습니다. 따라서 이러한 요인들이 북미 지역의 시장 성장을 견인하는 데 도움이 됩니다.

COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 이소시트레이트 탈수소효소 억제제 시장에 상당한 영향을 미쳤습니다. 2020년 초 팬데믹 발생으로 인해 광범위한 봉쇄와 제한 조치가 시행되었고, 이는 전 세계적으로 정기적인 진단, 치료, 제품 출시 및 상담에 영향을 미쳤습니다. 팬데믹 발생으로 인해 많은 제약 및 의료기기 제조 업체들이 인력 부족에 직면했고, 봉쇄 조치로 인해 직원들이 업무 현장으로 이동할 수 없었습니다. 따라서 이러한 요인들로 인해 이소시트레이트 탈수소효소 억제제 시장은 예측 기간 동안 중간 정도의 영향을 받을 것으로 예상됩니다.

시장 세분화
유형별
• IDH1 억제제
• IDH2 억제제
• 기타
적용 분야별
• 급성 골수성 백혈병
• 담관암
• 기타
투여 경로별
• 경구
• 주사
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Merck KGaA, Adooq Bioscience LLC, Agios Pharmaceuticals Inc., Rigel Pharmaceuticals Inc., Servier, Celgene Corporation, Bristol Myers Squibb, Philogen SpA 등이 있습니다.

주요 동향
• 2023년 5월, 세르비에 제약(Servier Pharmaceuticals)은 IDH1 변이 급성 골수성 백혈병 및 IDH1 변이 담관암 치료제인 티브소보(Tibsovo)에 대해 유럽 위원회의 승인을 받았습니다.
보고서 구매 이유

• 유형, 적용 분야, 투여 경로 및 지역별 글로벌 이소시트레이트 탈수소효소 억제제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴하기 위해

• 모든 세그먼트를 포함한 글로벌 이소시트레이트 탈수소효소 억제제 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트 제공

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 결과를 담은 PDF 보고서 제공

• 주요 기업의 핵심 제품 정보를 담은 엑셀 파일 형태의 제품 맵핑 제공

글로벌 이소시트레이트 탈수소효소 억제제 시장 보고서는 약 61개의 표, 69개의 그림, 185페이지 분량으로 구성됩니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Isocitrate Dehydrogenase Inhibitors Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.
Isocitrate Dehydrogenase Inhibitors alter the activity of IDH enzymes resulting in a reduction of α-ketoglutarate to D-2-hydroxyglutarate. Isocitrate dehydrogenase 1 (IDH1) inhibitors are drugs used for treating different types of cancers. IDH1 is a gene that makes an enzyme isocitrate dehydrogenase.
These inhibitors target mutated IDH enzymes hindering their abnormal activity and impeding cancer cell proliferation. The therapeutic aim is to induce differentiation and apoptosis in cancer cells by providing a targeted approach in oncology.
Market Dynamics
Increasing prevalence of acute myeloid leukemia
The increasing prevalence of acute myeloid leukemia acts as a significant driver for market growth. Acute myeloid leukemia progresses rapidly with myeloid cells interfering with the production of normal white blood cells, red blood cells, and platelets.
For instance, according to the American Society of Clinical Oncology, acute myeloid leukemia makes up 31% of all adult leukemia cases. It is estimated that 11,310 deaths from this disease occur in the United States in 2023.
Additionally, according to the Indian Council of Medical Research, its annual incidence is 2-3 per 100,000. The incidence increases with age and it is less than 1 per 100,000 under 30 years of age and 17 per 100,000 by 75 years.
Furthermore, significant growth drivers such as the rising clinical trials for isocitrate dehydrogenase inhibitors, and new drug approvals are expected to drive the market in the forecast period.
Side effects associated with isocitrate dehydrogenase inhibitors
The side effects of IDH inhibitors can hamper the market growth. Common side effects of isocitrate dehydrogenase inhibitors include fatigue, decreased hemoglobin level, decreased white blood cell count, increased cholesterol, nausea, and decreased electrolytes.
Segment Analysis
The global isocitrate dehydrogenase inhibitors market is segmented based on type, application, route of administration, and region.
The IDH1 Inhibitor segment accounted for approximately 41.9% of the market share
The IDH1 Inhibitor segment is expected to hold the largest market share over the period forecast due to the increasing number of clinical trials. A total number of 33 clinical trials were conducted for IDH 1 inhibitors.
For instance, according to clinicaltrial.gov, on March 1, 2021, M.D. Anderson Cancer Center started a clinical trial on the study of oral Decitabine/Cedazuridine and Venetoclax in combination with the targeted mutant idh1 inhibitor ivosidenib. It is currently in phase 2 trial and the expected study completion date is November 2024
Additionally, on January 4, 2023, Groupe Francophone des Myelodysplasies started a clinical trial on Phase II multicenter study of IDH1 inhibitor in patients with IDH1 mutated Myelodysplastic Syndrome. The expected study completion date is April 2023. Hence, due to the above factors, the segment is expected to hold the largest market share.
Geographical Analysis
North America is expected to hold a significant position in the global isocitrate dehydrogenase inhibitors market share
The global isocitrate dehydrogenase inhibitors market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.
North America has maintained a significant market proportion due to factors such as the rising prevalence of cholangiocarcinoma, drug approval, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
For instance, in December 2022, the FDA approved Rezlidhia (olutasidenib) capsules for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.
Additionally, an estimated 8,000 people in the United States are diagnosed with cholangiocarcinoma each year, and up to 20% of patients with cholangiocarcinoma harbor IDH1 mutations. Thus, the above factors help to drive the region’s growth.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global isocitrate dehydrogenase inhibitors market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatment, product launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the isocitrate dehydrogenase inhibitors market is expected to be moderately affected over the forecast period.
Market Segmentation
By Type
• IDH1 Inhibitor
• IDH2 Inhibitor
• Others
By Application
• Acute myeloid leukemia
• Cholangiocarcinoma
• Others
By Route of Administration
• Oral
• Parenteral
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Merck KGaA, Adooq Bioscience LLC, Agios Pharmaceuticals Inc., Rigel Pharmaceuticals Inc., Servier, Celgene Corporation, Bristol Myers Squibb, Philogen SpA among others.
Key Developments
• In May 2023, Servier Pharmaceuticals received European Commission approval for Tibsovo in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma.
Why Purchase the Report?
• To visualize the global isocitrate dehydrogenase inhibitors market segmentation based on type, application, route of administration and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global isocitrate dehydrogenase inhibitors market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global isocitrate dehydrogenase inhibitors market report would provide approximately 61 tables, 69 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by Route of Administration
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of acute myeloid leukemia
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side effects associated with isocitrate dehydrogenase inhibitors
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. IDH1 Inhibitor*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. IDH2 Inhibitor
7.4. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Acute myeloid leukemia*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cholangiocarcinoma
8.4. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Merck KGaA
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Adooq Bioscience LLC
12.3. Agios Pharmaceuticals Inc
12.4. Rigel Pharmaceuticals Inc.
12.5. Servier
12.6. Celgene Corporation
12.7. Bristol Myers Squibb
12.8. Philogen SpA
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Merck KGaA, 4.	Key Developments, Adooq Bioscience LLC, Agios Pharmaceuticals Inc, Rigel Pharmaceuticals Inc., Servier, Celgene Corporation, Bristol Myers Squibb, Philogen SpA

표 목록 (Tables)

List of Tables

Table 1 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Type, 2022-2031 (US$ Million)

Table 7 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Application, 2022-2031 (US$ Million)

Table 9 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 11 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Isocitrate Dehydrogenase Inhibitors Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Isocitrate Dehydrogenase Inhibitors Market Value, By Type, 2022-2031 (US$ Million)

Table 14 North America Isocitrate Dehydrogenase Inhibitors Market Value, By Application, 2022-2031 (US$ Million)

Table 15 North America Isocitrate Dehydrogenase Inhibitors Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 16 North America Isocitrate Dehydrogenase Inhibitors Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Isocitrate Dehydrogenase Inhibitors Market Value, By Type, 2022-2031 (US$ Million)

Table 18 South America Isocitrate Dehydrogenase Inhibitors Market Value, By Application, 2022-2031 (US$ Million)

Table 19 South America Isocitrate Dehydrogenase Inhibitors Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 20 South America Isocitrate Dehydrogenase Inhibitors Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Isocitrate Dehydrogenase Inhibitors Market Value, By Type, 2022-2031 (US$ Million)

Table 22 Europe Isocitrate Dehydrogenase Inhibitors Market Value, By Application, 2022-2031 (US$ Million)

Table 23 Europe Isocitrate Dehydrogenase Inhibitors Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 24 Europe Isocitrate Dehydrogenase Inhibitors Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Value, By Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Value, By Application, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Value, By Type, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Value, By Application, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 32 Merck KGaA: Overview

Table 33 Merck KGaA: Product Portfolio

Table 34 Merck KGaA: Key Developments

Table 35 Adooq Bioscience LLC: Overview

Table 36 Adooq Bioscience LLC: Product Portfolio

Table 37 Adooq Bioscience LLC: Key Developments

Table 38 Agios Pharmaceuticals Inc: Overview

Table 39 Agios Pharmaceuticals Inc: Product Portfolio

Table 40 Agios Pharmaceuticals Inc: Key Developments

Table 41 Rigel Pharmaceuticals Inc.: Overview

Table 42 Rigel Pharmaceuticals Inc.: Product Portfolio

Table 43 Rigel Pharmaceuticals Inc.: Key Developments

Table 44 Servier : Overview

Table 45 Servier : Product Portfolio

Table 46 Servier : Key Developments

Table 47 Celgene Corporation: Overview

Table 48 Celgene Corporation: Product Portfolio

Table 49 Celgene Corporation: Key Developments

Table 50 Bristol Myers Squibb : Overview

Table 51 Bristol Myers Squibb : Product Portfolio

Table 52 Bristol Myers Squibb : Key Developments

Table 53 Philogen SpA: Overview

Table 54 Philogen SpA: Product Portfolio

Table 55 Philogen SpA: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 2 Global Isocitrate Dehydrogenase Inhibitors Market Share, By Type, 2023 & 2031 (%)

Figure 3 Global Isocitrate Dehydrogenase Inhibitors Market Share, By Application, 2023 & 2031 (%)

Figure 4 Global Isocitrate Dehydrogenase Inhibitors Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 5 Global Isocitrate Dehydrogenase Inhibitors Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Isocitrate Dehydrogenase Inhibitors Market Y-o-Y Growth, By Type, 2023-2031 (%)

Figure 7 IDH1 Inhibitor Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 8 IDH2 Inhibitor Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 9 Others Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 10 Global Isocitrate Dehydrogenase Inhibitors Market Y-o-Y Growth, By Application, 2023-2031 (%)

Figure 11 Acute Myeloid Leukemia Application in Global Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 12 Cholangiocarcinoma Application in Global Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 13 Others Application in Global Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 14 Global Isocitrate Dehydrogenase Inhibitors Market Y-o-Y Growth, By Route of Administration, 2023-2031 (%)

Figure 15 Oral Route of Administration in Global Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 16 Parenteral Route of Administration in Global Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 17 Global Isocitrate Dehydrogenase Inhibitors Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 18 North America Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 19 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 20 Europe Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 21 South America Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 22 Middle East and Africa Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 23 North America Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 24 North America Isocitrate Dehydrogenase Inhibitors Market Share, By Type, 2023 & 2031 (%)

Figure 25 North America Isocitrate Dehydrogenase Inhibitors Market Share, By Application, 2023 & 2031 (%)

Figure 26 North America Isocitrate Dehydrogenase Inhibitors Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 27 North America Isocitrate Dehydrogenase Inhibitors Market Share, By Country, 2023 & 2031 (%)

Figure 28 South America Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 29 South America Isocitrate Dehydrogenase Inhibitors Market Share, By Type, 2023 & 2031 (%)

Figure 30 South America Isocitrate Dehydrogenase Inhibitors Market Share, By Application, 2023 & 2031 (%)

Figure 31 South America Isocitrate Dehydrogenase Inhibitors Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 32 South America Isocitrate Dehydrogenase Inhibitors Market Share, By Country, 2023 & 2031 (%)

Figure 33 Europe Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 34 Europe Isocitrate Dehydrogenase Inhibitors Market Share, By Type, 2023 & 2031 (%)

Figure 35 Europe Isocitrate Dehydrogenase Inhibitors Market Share, By Application, 2023 & 2031 (%)

Figure 36 Europe Isocitrate Dehydrogenase Inhibitors Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 37 Europe Isocitrate Dehydrogenase Inhibitors Market Share, By Country, 2023 & 2031 (%)

Figure 38 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 39 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Share, By Type, 2023 & 2031 (%)

Figure 40 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Share, By Application, 2023 & 2031 (%)

Figure 41 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 42 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Share, By Country, 2023 & 2031 (%)

Figure 43 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Value, 2022-2031 (US$ Million)

Figure 44 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Share, By Type, 2023 & 2031 (%)

Figure 45 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Share, By Application, 2023 & 2031 (%)

Figure 46 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 47 Merck KGaA: Financials

Figure 48 Adooq Bioscience LLC: Financials

Figure 49 Agios Pharmaceuticals Inc: Financials

Figure 50 Rigel Pharmaceuticals Inc.: Financials

Figure 51 Servier : Financials

Figure 52 Celgene Corporation: Financials

Figure 53 Bristol Myers Squibb : Financials

Figure 54 Philogen SpA: Financials

글로벌 이소시트르산 탈수소효소 억제제 시장 – 2023-2030

Global Isocitrate Dehydrogenase Inhibitors Market - 2023-2030